Gouvea, E S
Ota, V K
Noto, C
Santoro, M L
Spindola, L M
Moretti, P N
Carvalho, C M
Xavier, G
Rios, A C
Sato, J R
Hayashi, M A F
Brietzke, E
Gadelha, A
Bressan, R A
Cordeiro, Q
Belangero, S I
Article History
Received: 2 May 2016
Revised: 23 June 2016
Accepted: 12 July 2016
First Online: 4 October 2016
Competing interests
: CN has received a scholarship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and has served as a consultant or advisory board member for Janssen. AG was on the speakers’ bureau and/or has acted as a consultant for Janssen-Cilag in the last 12 months and has also received research support from Brazilian government institutions (CNPq). EB has been supported by CNPq, CAPES and FAPESP. RAB has received research funding from FAPESP, CNPq, CAPES, Fundação Safra, Fundação ABADS, Janssen, Eli Lilly, Lundbeck, Novartis and Roche, has served as a speaker for Astra Zeneca, Bristol, Janssen, Lundbeck and Revista Brasileira de Psiquiatria and is a shareholder of Radiopharmacus Ltda and Biomolecular Technology. The remaining authors declare no conflict of interest.